Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Oncology and palliative care indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Recognising possible cancer and urgent referral

Oncology and palliative care · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Airway compromise, superior vena cava obstruction, spinal cord compression, pathological fracture, uncontrolled bleeding, bowel obstruction, severe hypercalcaemia, neutropenic sepsis or rapidly worsening neurological deficit requires same-day acute assessment. Stabilisation and urgent imaging or specialist treatment must not wait for a routine suspected-cancer appointment.

Overview

Recognise symptom patterns that may represent cancer, identify emergencies, use current NICE referral routes and direct-access tests, and safety-net patients whose initial probability remains uncertain.

Possible cancer often presents through common symptoms: bleeding, change in bowel habit, cough, dysphagia, weight loss, fatigue, lymphadenopathy, persistent pain or a new mass. The task is not to diagnose malignancy in primary care but to recognise when probability and potential harm justify urgent investigation. NICE NG12 supplies symptom-, sign- and test-based routes, including direct-access investigation and urgent suspected-cancer referral. Local services determine operational booking without changing the clinical need.

Referral urgency differs from physiological emergency. A patient with a stable suspicious lesion can use an urgent diagnostic pathway; a patient with stridor, cord compression, major haemorrhage or obstruction requires acute care immediately. Baseline tests can identify anaemia, organ dysfunction and competing diagnoses, but extensive low-yield testing should not delay the recommended definitive route. Tumour markers are rarely suitable general screening tests for undifferentiated symptoms.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Oncology and palliative careOriginal SBA

Cord compression presentation

A patient without a previous cancer diagnosis has progressive thoracic back pain, new bilateral leg weakness and urinary retention. What is the safest next step?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Oncology and palliative care topics →
Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG12 suspected cancer recommendationsCurrent symptom, sign and investigation triggers for urgent cancer pathways.
  • NHS England cancer programmeEarlier diagnosis, pathway standards and equitable access to cancer services.
  • NICE shared decision making recommendationsCommunication of uncertainty, referral options and decisions in accessible formats.
  • Royal College of Pathologists cancer datasetsTissue confirmation and structured reporting after urgent referral.
  • NICE NG234 spinal metastases and metastatic spinal cord compressionEmergency recognition, immobilisation, MRI and treatment pathways for suspected metastatic spinal cord compression.
  • UKONS acute oncology initial management guidelinesCurrent UK acute-oncology emergency algorithms and escalation principles.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem ·

Safety-netting is part of diagnosis. Record the working differential, why cancer is possible, what was requested, when results or appointments should occur and who will act. If a test is normal but the symptom continues, reassess the original probability rather than treating the result as absolute. People should know how and when to return, including earlier triggers.

Key points

  • Cancer recognition combines symptom, examination, age, duration, risk factors and trajectory; no single red flag is sufficiently sensitive to exclude disease when absent.
  • Use the current NICE NG12 site-based or symptom-based recommendations and local referral form rather than memorised historical thresholds.
  • An urgent suspected-cancer referral means cancer must be excluded promptly; it does not mean that cancer is the most likely diagnosis.
  • Some pathways begin with a primary-care test such as chest radiography, full blood count, FIT, CA125 or ultrasound, but the correct sequence is symptom-specific.
  • A normal initial test does not close the case when symptoms persist, progress or remain discordant with the result.
  • Explain the reason for referral, expected contact time and how to chase a missing appointment; unclear language increases non-attendance and distress.
  • Safety-net every unresolved presentation with a named review interval, trigger symptoms and ownership of outstanding results.
  • Consider cancer in people with multimorbidity and in younger adults when the pattern is unusual; diagnostic overshadowing causes delayed diagnosis.

Aetiology

01

Local primary cancer

A developing tumour can cause bleeding, obstruction, ulceration, mass effect or organ dysfunction before producing systemic symptoms.

02

Metastatic presentation

Cancer may first appear through bone pain, neurological deficit, lymphadenopathy, thrombosis, hypercalcaemia or failure of an organ distant from the primary.

03

Benign and inflammatory mimics

Common infection, medication effects, inflammatory disease and benign structural lesions produce similar symptoms, so referral expresses risk rather than a diagnosis.

Pathophysiology

  1. 1
    Clonal growth disrupts tissue

    Expanding malignant cells replace or compress normal structures, invade basement membranes and alter local blood vessels, producing mass, pain, bleeding or obstruction.

  2. 2
    Systemic signalling develops

    Inflammatory cytokines, catabolism, marrow infiltration and ectopic hormone production can cause weight loss, fatigue, cytopenias or paraneoplastic biochemical change.

  3. 3
    Dissemination creates emergencies

    Lymphatic, haematogenous or direct spread can compromise spinal cord, airway, major vessels, bowel, bone or brain before the primary tumour is recognised.

Clinical features and red flags

Unexplained bleeding

Haemoptysis, postmenopausal bleeding, visible haematuria, rectal bleeding or persistent intermenstrual bleeding requires site- and age-specific assessment.

Progressive obstructive symptomRed flag

Increasing dysphagia, jaundice, bowel obstruction, stridor or urinary obstruction suggests structural disease and may need acute rather than outpatient care.

New persistent mass

A breast, testicular, neck, abdominal, pelvic or soft-tissue mass is characterised by duration, fixation, growth, nodes and systemic features.

Systemic trajectory

Unintentional weight loss, drenching sweats, persistent fatigue, thrombosis or unexplained laboratory change gains significance when progressive or combined.

Metastatic emergencyRed flag

New focal weakness, sphincter disturbance, severe bone pain, confusion or hypercalcaemic dehydration may be the first cancer presentation.

Investigations

  1. 01
    Focused history and examinationFirst step
    Why
    Localise the likely organ system and identify emergency complications.
    Interpretation and limitations
    Document duration, progression, relevant exposure, family history and negative findings that affect the specific NG12 route.
  2. 02
    Symptom-directed primary-care test
    Why
    Use the recommended initial investigation where guidance places testing before referral.
    Interpretation and limitations
    Examples differ by presentation; interpret the result within the referral algorithm and do not substitute unrelated tumour markers.
  3. 03
    Baseline full blood count and biochemistry
    Why
    Detect anaemia, cytopenia, cholestasis, kidney injury or hypercalcaemia that changes urgency.
    Interpretation and limitations
    Normal results do not exclude localised cancer, while severe abnormalities may require same-day treatment and specialist discussion.
  4. 04
    Urgent site-specific imaging or endoscopy
    Why
    Visualise the suspected primary and obtain tissue where appropriate.
    Interpretation and limitations
    The specialist pathway selects modality and biopsy route to preserve staging and resectability; primary care should avoid poorly planned biopsy.
  5. 05
    Histopathology
    Why
    Confirm malignancy and subtype before definitive treatment.
    Interpretation and limitations
    Adequacy, grade, biomarkers and tissue origin guide staging and treatment; inconclusive tissue requires MDT-directed repeat sampling.

Differential diagnosis

01

Benign site-specific disease

Haemorrhoids, fibroids, cysts, reflux and other common disorders often explain symptoms, but persistent or progressive features still require appropriate exclusion.

02

Infection or inflammation

Chronic infection, autoimmune disease and granulomatous disorders can cause weight loss, nodes, imaging abnormalities and laboratory changes that resemble malignancy.

03

Medicine-related effect

Anticoagulants, hormones, immunosuppressants and other medicines can cause bleeding or constitutional change while also modifying underlying cancer risk.

04

Haematological or metabolic illness

Anaemia, endocrine disease, liver failure and other systemic disorders may reproduce cancer-associated fatigue, weight change or biochemical disturbance.

Management

01EmergencyStabilise a cancer complicationFirst stepThe presentation includes airway, neurological, haemorrhagic, obstructive or metabolic instability.+
  1. 1Use ABCDE assessment, treat immediate physiology and contact the relevant acute oncology, surgical, critical-care or site team.
  2. 2Obtain urgent targeted imaging and blood tests without allowing the absence of a known cancer diagnosis to delay emergency treatment.
  3. 3After stabilisation, coordinate tissue diagnosis and staging so emergency intervention does not fragment the longer cancer pathway.
02ReferUse the current suspected-cancer routeThe symptom, sign or test meets NICE or local urgent-referral criteria without acute instability.+
  1. 1Select the site-specific or non-site-specific pathway, attach the relevant examination, test results and communication needs, and state diagnostic uncertainty honestly.
  2. 2Tell the person why cancer needs exclusion, what the pathway involves and when contact should occur; provide a route to chase delay.
  3. 3Track referral acceptance and attendance, responding to service redirection rather than assuming another team owns the unresolved risk.
03ReviewSafety-net residual uncertaintyInitial tests or specialist assessment do not explain a persistent concerning symptom.+
  1. 1Set a specific review date based on symptom risk and expected resolution, with earlier return triggers for deterioration.
  2. 2AlternativeCheck outstanding results and reconsider the differential, including alternative cancer site, inflammatory disease and treatment effects.
  3. 3EscalationEscalate or re-refer when trajectory and test result disagree; repeated reassurance without reassessment is not safety-netting.

Complications

01

Diagnostic delay

Missed referral, false reassurance or untracked results allow a potentially curable tumour to progress and increase the intensity of later treatment.

02

Acute organ compromise

Airway obstruction, spinal cord compression, severe bleeding, bowel obstruction and metabolic emergencies can cause irreversible harm before histological confirmation.

03

Psychological and access harm

Unclear communication creates fear or non-attendance, while inaccessible appointments can widen diagnostic delay for already underserved groups.

Monitoring and follow-up

  • Maintain a results log showing requested test, expected date, result, communication and responsible clinician.
  • Confirm urgent referral receipt and attendance, especially where language, learning disability, transport or deprivation creates access barriers.
  • Reassess symptom trajectory rather than simply repeating the same test when an unexplained feature persists.
  • Monitor anaemia, calcium, renal, hepatic or coagulation abnormalities when they create immediate treatment risk.
  • Document patient understanding of the referral and the exact symptoms that should trigger emergency attendance.

Special situations

Urgent is not certain

Clear explanation avoids the twin harms of telling someone they have cancer and falsely reassuring them that referral is merely routine.

Normal tests are conditional

A result is reassuring only to the sensitivity of that test, the disease stage and the correctness of the original pathway.

Tumour markers are selective

Most lack sufficient specificity for general symptom triage and can cause false reassurance or cascades when used indiscriminately.

Comorbidity can conceal

Weight loss, anaemia or pain may be attributed to chronic disease, but a new trajectory still requires independent explanation.

Safety-net has ownership

A time, trigger and responsible professional are necessary; simply advising return if worried leaves failure points invisible.

Common pitfalls

  1. 01

    Using screening instead of diagnostic testing.

  2. 02

    Waiting for multiple red flags to coexist.

  3. 03

    Sending an unstable patient to routine clinic.

  4. 04

    Ordering broad tumour markers before localisation.

  5. 05

    Failing to explain the urgent referral.

  6. 06

    Assuming a normal first test ends assessment.

  7. 07

    Leaving referral or result ownership unclear.

Content changes
Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom